STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, in the firstline treatment of locally advanced and/or metastatic Renal cancer
Phase of Trial: Phase II/III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms STAR
- 04 Apr 2018 Status changed from recruiting to completed.
- 17 Dec 2015 Accrual to date is 54% according to the United Kingdom Clinical Research Network record.
- 04 Nov 2015 Accrual to date is 50% according to the United Kingdom Clinical Research Network record.